ARDS

Nov 20, 2024

Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the u...

Nov 20, 2024

Acute respiratory distress syndrome (ARDS) is a rapidly progressing condition that affects critically ill people. The major complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible. Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart...

Nov 20, 2024

The acute respiratory distress syndrome (ARDS) prevalence is increasing every year; it is estimated that in the United States alone, about 190K Americans are diagnosed with ARDS each year. Prior to the COVID-19 global pandemic, more than 700K individuals in the US and 2 million cases globally developed ARDS from tr...

Nov 20, 2024

Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition characterized by acute respiratory distress syndrome symptoms such as rapid onset of noncardiogenic pulmonary edema and hypoxemia. This life-threatening condition is a leading cause of respiratory failure, particularly in infants and critically i...

Jun 09, 2020

Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...

Apr 15, 2020

The Novel Coronavirus since its outbreak in Wuhan China in November-2019 has infected around 1,848,439 people with 117,217 confirmed deaths in 213 countries, till date.  Countries around the world are working tirelessly to tackle the current situation. Local Governments in order to reduce the pace of corona...

Apr 14, 2020

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...